Innovative albumin-based material produced using a non-denaturing process to preserve the structure of the protein and allow the loading of sensitive chemical/biological molecules. Albumin is a natural drug carrier with low immunogenicity: good candidate for easily functionalisable biomaterials. Targeted applications: Implantable Medical Device for human/veterinary controlled release of drugs.

Medical needles are used in mini-invasive percutaneous procedures and are deep-tissue inserted. ARC technology adds a mechanical option to medical needles allowing the correction of its trajectory and thus better reach the targeted tissue. Its main applications are biopsy and cancerous lesion treatment.

ATK develops a NCE with selective positive modulation of TrkB activation by BDNF (PAM). Neuroprotection potential for various neurodegenerative diseases as Alzheimer’s, Parkinson’s, or Huntington diseases. Small molecule crossing blood-brain barrier with high TrkB affinity and selectivity.
In vivo PoC in Huntington Disease.

Nouvelles résines pour améliorer la protection balistique. Résines photopolymérisables rapidement sur les tissus d'aramide permettant la protection contre les balles et les fragments des véhicules et des personnes. Sans composés organiques volatils, le matériau préserve la santé des utilisateurs. Particulièrement adaptée aux véhicules blindés pour un coût d'équipements et d'utilisation avantageux.

New-infrared coating and implantable materials used as medical biosensors. Targeted applications for this new functionalized biomaterial: diagnostic detection for inflammatory and infectious processes, monitoring of patients suffering from chronic inflammatory diseases, monitoring of patients during or after surgical interventions

Phytopharmaceutical agents for the treatment of grapevine trunk diseases. Two complementary formulations based on Bismuth Subsalicylate (BSS): 
- a curative formulation that can be injected by endotherapy 
- a light-curing formulation for the protection of pruning wound that can be painted on
High unmeet need: no efficient curative solution in the market.

Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.

This project aims at increasing the therapeutic window of ADCs by developing a linker that releases the payload selectively in cancerous cells.
Using cytometric screening technology, we identified a new linker with unprecedented selectivity for cancer cells which express specific enzymes.

Development of new photopolymerisable formulations (under UV or near-infrared LED light) for epoxy-amines resins. These formulations allow a polymerisation within minutes instead of hours, at room temperature without the necessity of thermal cure. Their application is in various fields and markets, such as composites, adhesives etc.

Restoring apelin signaling in sarcopenia considerably enhanced muscles’ function and regenerative capacity. GlucoFAP13 project proposes apelin-13 derivatives stabilized by an innovative technology. Evaluation ongoing for efficacy in improving muscle strength, stamina and endurance in a sarcopenic mouse model.